IN2015DN01361A - - Google Patents

Info

Publication number
IN2015DN01361A
IN2015DN01361A IN1361DEN2015A IN2015DN01361A IN 2015DN01361 A IN2015DN01361 A IN 2015DN01361A IN 1361DEN2015 A IN1361DEN2015 A IN 1361DEN2015A IN 2015DN01361 A IN2015DN01361 A IN 2015DN01361A
Authority
IN
India
Prior art keywords
antibodies
fusion proteins
constant regions
incorporating
igg
Prior art date
Application number
Other languages
English (en)
Inventor
Naoya Tsurushita
J Yun Tso
Original Assignee
Jn Biosciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jn Biosciences Llc filed Critical Jn Biosciences Llc
Publication of IN2015DN01361A publication Critical patent/IN2015DN01361A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
IN1361DEN2015 2012-08-02 2013-07-31 IN2015DN01361A (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261679045P 2012-08-02 2012-08-02
US201361767724P 2013-02-21 2013-02-21
PCT/US2013/053086 WO2014022592A1 (en) 2012-08-02 2013-07-31 Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece

Publications (1)

Publication Number Publication Date
IN2015DN01361A true IN2015DN01361A (de) 2015-07-03

Family

ID=50025683

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1361DEN2015 IN2015DN01361A (de) 2012-08-02 2013-07-31

Country Status (7)

Country Link
US (1) US9540442B2 (de)
EP (1) EP2880057A4 (de)
JP (1) JP2015524821A (de)
CN (1) CN104684928A (de)
CA (1) CA2879814A1 (de)
IN (1) IN2015DN01361A (de)
WO (1) WO2014022592A1 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8759297B2 (en) 2006-08-18 2014-06-24 Armagen Technologies, Inc. Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns
US8974791B2 (en) 2007-07-27 2015-03-10 Armagen Technologies, Inc. Methods and compositions for increasing α-L-iduronidase activity in the CNS
ES2725200T3 (es) 2009-10-09 2019-09-20 Armagen Inc Métodos y composiciones para aumentar la actividad de iduronato 2-sulfatasa en el SNC
US11147852B2 (en) 2011-12-23 2021-10-19 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
US9969813B2 (en) 2012-05-10 2018-05-15 Bioatla, Llc Multi-specific monoclonal antibodies
CN104684928A (zh) 2012-08-02 2015-06-03 Jn生物科学有限责任公司 通过半胱氨酸突变和μ尾端多聚化的抗体或融合蛋白
AU2015226101B2 (en) * 2014-03-05 2019-08-22 Ucb Biopharma Sprl Multimeric Fc proteins
MX2016010951A (es) * 2014-03-05 2016-11-29 Ucb Biopharma Sprl Proteinas de fc multimericas.
IL292311A (en) 2014-04-03 2022-06-01 Igm Biosciences Inc J-chain qualified
MA47849A (fr) 2014-05-28 2020-01-29 Agenus Inc Anticorps anti-gitr et leurs procédés d'utilisation
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
SI3235830T1 (sl) * 2014-12-19 2020-12-31 Jiangsu Hengrui Medicine Co., Ltd. Proteinski kompleks interlevkina 15 in njegove uporabe
US10538589B2 (en) * 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
IL284430B2 (en) 2015-01-20 2024-04-01 Igm Biosciences Inc Tumor necrosis factor-α receptor binding molecules and their uses
US10787520B2 (en) * 2015-03-04 2020-09-29 Igm Biosciences, Inc. Multimeric bispecific binding molecules specific for CD20 and CD3
CA2980751A1 (en) * 2015-03-25 2016-09-29 Stephen F. Carroll Multi-valent hepatitis b virus antigen binding molecules and uses thereof
CN107709364A (zh) * 2015-04-07 2018-02-16 豪夫迈·罗氏有限公司 具有激动剂活性的抗原结合复合体及使用方法
CN107847591B (zh) * 2015-04-17 2023-07-28 Igm生物科学股份有限公司 多价人免疫缺陷病毒抗原结合分子及其应用
US10259882B2 (en) 2015-05-07 2019-04-16 Agenus Inc. Anti-OX40 antibodies
CN108463245A (zh) 2015-09-30 2018-08-28 Igm生物科学有限公司 具有修饰的j链的结合分子
JP7058213B2 (ja) 2015-09-30 2022-04-21 アイジーエム バイオサイエンシズ インコーポレイテッド 改変ｊ鎖を有する結合分子
KR20180069066A (ko) 2015-10-30 2018-06-22 갤럭시 바이오테크, 엘엘씨 사멸 수용체 4 및 사멸 수용체 5에 결합하는 매우 강력한 항체
CA2949033A1 (en) * 2015-11-30 2017-05-30 Pfizer Inc. Antibodies and antibody fragments for site-specific conjugation
TWI726942B (zh) 2015-11-30 2021-05-11 美商輝瑞股份有限公司 位點專一性ｈｅｒ２抗體藥物共軛體
US11447557B2 (en) 2015-12-02 2022-09-20 Agenus Inc. Antibodies and methods of use thereof
EP3402507A4 (de) * 2016-01-11 2019-08-07 Inhibrx, Inc. Multivalente und multispezifische ox40-bindende fusionsproteine
AU2017238172A1 (en) 2016-03-21 2018-09-13 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
JP7106187B2 (ja) 2016-05-11 2022-07-26 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックスを保存する方法
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
CN109071613A (zh) 2016-05-11 2018-12-21 通用电气医疗集团生物工艺研发股份公司 分离基质
JP6987424B2 (ja) 2016-05-11 2022-01-05 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックスを洗浄および／または消毒する方法
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
CA3030640A1 (en) * 2016-07-20 2018-01-25 Igm Biosciences, Inc. Multimeric cd40 binding molecules and uses thereof
CA3030634A1 (en) * 2016-07-20 2018-01-25 Igm Biosciences, Inc. Multimeric cd137/4-1bb binding molecules and uses thereof
MA46770A (fr) 2016-11-09 2019-09-18 Agenus Inc Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
WO2018151820A1 (en) 2017-02-16 2018-08-23 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
EP3630836A1 (de) 2017-05-31 2020-04-08 Elstar Therapeutics, Inc. Multispezifische moleküle, die an myeloproliferatives leukämie (mlp)-protein binden, und deren verwendungen
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
US11364303B2 (en) 2017-09-29 2022-06-21 Pfizer Inc. Cysteine engineered antibody drug conjugates
AU2018347607A1 (en) 2017-10-14 2020-03-26 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
US20210238280A1 (en) 2018-03-14 2021-08-05 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
EP3765516A2 (de) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunktionale moleküle und verwendungen davon
DE202019005887U1 (de) 2018-07-03 2023-06-14 Marengo Therapeutics, Inc. Anti-TCR-Antikörpermoleküle und Verwendungen davon
KR102232659B1 (ko) * 2018-07-16 2021-03-26 전북대학교 산학협력단 항원전달용 폴리펩타이드, 이를 포함하는 Fc-융합 단백질 및 이의 용도
MX2021001703A (es) 2018-08-13 2021-04-19 Inhibrx Inc Polipeptidos de union a ox40 y sus usos.
US20220064263A1 (en) * 2018-12-27 2022-03-03 Kindred Biosciences, Inc. IGG FC Variants for Veterinary Use
CN114026122A (zh) 2019-02-21 2022-02-08 马伦戈治疗公司 结合t细胞相关癌细胞的多功能分子及其用途
JP2022521750A (ja) 2019-02-21 2022-04-12 マレンゴ・セラピューティクス，インコーポレーテッド カルレティキュリンに結合する多機能性分子およびその使用
JP2022521937A (ja) 2019-02-21 2022-04-13 マレンゴ・セラピューティクス，インコーポレーテッド ＮＫｐ３０に結合する抗体分子およびその使用
CN114126714A (zh) 2019-02-21 2022-03-01 马伦戈治疗公司 抗tcr抗体分子及其用途
CA3130628A1 (en) 2019-02-21 2020-08-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
EP4084821A4 (de) 2020-01-03 2024-04-24 Marengo Therapeutics Inc An cd33 bindende multifunktionsmoleküle und ihre verwendungen
EP4139363A1 (de) 2020-04-24 2023-03-01 Marengo Therapeutics, Inc. An t-zellen-verwandte krebszellen bindende multifunktionelle moleküle und verwendungen davon
EP4204458A1 (de) 2020-08-26 2023-07-05 Marengo Therapeutics, Inc. Verfahren zum nachweis von trbc1 oder trbc2
KR20230074144A (ko) 2020-08-26 2023-05-26 마렝고 테라퓨틱스, 인크. NKp30에 결합하는 항체 분자 및 이의 용도
AU2021331075A1 (en) 2020-08-26 2023-04-06 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
KR20220029343A (ko) 2020-08-31 2022-03-08 (주)메디톡스 항-ｖｅｇｆ 육량체 항체, 및 이를 포함하는 조성물
KR20220029524A (ko) 2020-08-31 2022-03-08 (주)메디톡스 항-ｖｅｇｆ 육량체 항체, 및 이를 포함하는 조성물
WO2022216993A2 (en) 2021-04-08 2022-10-13 Marengo Therapeutics, Inc. Multifuntional molecules binding to tcr and uses thereof
CN115724985A (zh) * 2021-08-27 2023-03-03 三生国健药业（上海）股份有限公司 一种cdc平台抗体

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020147326A1 (en) * 1996-06-14 2002-10-10 Smithkline Beecham Corporation Hexameric fusion proteins and uses therefor
GB9720054D0 (en) * 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
US6475749B1 (en) * 1999-08-11 2002-11-05 The Regents Of The University Of California Rh hybrid antibody
US20090068178A1 (en) * 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
CN101124245A (zh) * 2003-11-12 2008-02-13 比奥根艾迪克Ma公司 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法
JP2008504002A (ja) * 2003-11-12 2008-02-14 バイオジェン・アイデック・エムエイ・インコーポレイテッド 新生児Ｆｃレセプター（ＦｃＲｎ）結合ポリペプチド改変体、ダイマーＦｃ結合タンパク質、およびそれらに関連する方法
JPWO2008032833A1 (ja) * 2006-09-14 2010-01-28 株式会社医学生物学研究所 Ａｄｃｃ活性を増強させた抗体及びその製造方法
GB0922209D0 (en) 2009-12-18 2010-02-03 Univ Nottingham Proteins, nucleic acid molecules and compositions
CN103974977A (zh) * 2011-09-26 2014-08-06 Jn生物科学有限责任公司 杂交恒定区
CN104684928A (zh) 2012-08-02 2015-06-03 Jn生物科学有限责任公司 通过半胱氨酸突变和μ尾端多聚化的抗体或融合蛋白

Also Published As

Publication number Publication date
US9540442B2 (en) 2017-01-10
JP2015524821A (ja) 2015-08-27
CA2879814A1 (en) 2014-02-06
US20140037621A1 (en) 2014-02-06
EP2880057A1 (de) 2015-06-10
WO2014022592A1 (en) 2014-02-06
EP2880057A4 (de) 2016-03-23
CN104684928A (zh) 2015-06-03

Similar Documents

Publication Publication Date Title
IN2015DN01361A (de)
MX2010006767A (es) Anticuerpos de virus de hepatitis c.
CY1120414T1 (el) Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους
CA2849765C (en) Hybrid constant regions
CY1120412T1 (el) Μορια εξανθρωπισμενου αντισωματος ειδικα για il-31
MX2017006323A (es) Anticuerpos que comprenden regiones constantes pesadas modificadas.
PH12016501691A1 (en) Antibodies to matrix metalloproteinase 9
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
NZ706232A (en) Anti-cd3 antibodies and uses thereof
EA201390923A1 (ru) Модифицированное антитело с улучшенным полупериодом существования
IN2014MN00873A (de)
AR084210A1 (es) PROTEINAS DE UNION AL TNF-a
NZ600262A (en) Anti-her3 antibodies and uses thereof
DK2681244T3 (da) Cea-antistoffer
NZ578844A (en) Human cytomegalovirus neutralising antibodies and use thereof
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
MX2018007630A (es) Anticuerpos contra la metaloproteinasa de matriz 9.
EA201591407A1 (ru) Антитела, содержащие химерные константные домены
NZ726258A (en) Antibodies and uses thereof to detect folate receptor 1
NZ591056A (en) Human cytomegalovirus neutralizing antibodies and use thereof
NZ597447A (en) Humanised antibodies to toll-like receptor 2 and uses thereof
EA201490745A1 (ru) Полипептиды антител, которые вызывают антагонизм cd40l
UA106070C2 (uk) Антитіло, що специфічно зв'язується з egfr і her3
NZ594682A (en) Fully human antibodies specific to cadm1
PH12014501931A1 (en) Antibodies to matrix metalloproteinase 9